Understanding the Market | XTALPI rose nearly 7% in the morning session as the company signed a letter of intent for cooperation with Bio-S to jointly promote AI new drug research and development cooperation
I'm PortAI, I can summarize articles.
XTALPI rose nearly 7% in early trading, with its stock price doubling since early August, currently reported at HKD 12.37. The company signed a letter of intent for cooperation with Bio-S, and both parties will jointly promote new drug research and development using AI technology, targeting clinical needs in various disease areas. GF Securities pointed out that XTALPI, as a third-party service provider for AI-driven drug development, emphasizes technological neutrality and is expected to become an industry infrastructure in the future, with a sustainable business model and broad market space
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments